File Download
Supplementary
-
Citations:
- Appears in Collections:
postgraduate thesis: Adducin 3 and temozolomide resistance in glioblastoma multiforme
Title | Adducin 3 and temozolomide resistance in glioblastoma multiforme |
---|---|
Authors | |
Issue Date | 2012 |
Publisher | The University of Hong Kong (Pokfulam, Hong Kong) |
Citation | Zhuang, T. [莊天放]. (2012). Adducin 3 and temozolomide resistance in glioblastoma multiforme. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4833509 |
Abstract | Glioblastoma multiforme (GBM), a grade IV malignant astrocytic tumor according to WHO classification, is one of the most common and malignant brain tumor. Temozolomide (TMZ) is the current standard treatment for GBM. Nevertheless, resistance to chemotherapy in GBM is common and therefore a major obstacle to successful treatment. Adducin 3 (ADD3), a cytoskeletal protein, has been found to be associated with chemoresistance in osteosarcoma, but its potential role in glioblastoma is unclear. A TMZ-resistant model was established by chronically exposing the glioma cells (D54 cell line) to an increasing dose of TMZ. A resistant subclone (D54-R) was successfully generated. ADD3 expression level was found to be upregulated in the D54-R when compared to the parental D54 cells (D54-C).
CD133 is a putative cancer stem cell marker. Its expression level was found also to be higher in D54-R when compared to D54-C cells. Among the D54-R cells, a subgroup of cells was found to express ADD3 intensely. The proportion of these spherical cells was higher in D54-R than D54-C. Moreover, these cells were spherical in morphology and expressed putative cancer stem cell markers: CD133, NANOG and OCT-3/-4. Therefore, ADD3 is associated with cancer stem cells in human glioma. The upregulation of ADD3 expression is associated with TMZ-resistance in GBM. |
Degree | Master of Research in Medicine |
Subject | Glioblastoma multiforme - Chemotherapy. Drug resistance in cancer cells. Cytoskeletal proteins. |
Dept/Program | Surgery |
Persistent Identifier | http://hdl.handle.net/10722/174269 |
HKU Library Item ID | b4833509 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhuang, Tin-fong. | - |
dc.contributor.author | 莊天放. | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | Zhuang, T. [莊天放]. (2012). Adducin 3 and temozolomide resistance in glioblastoma multiforme. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4833509 | - |
dc.identifier.uri | http://hdl.handle.net/10722/174269 | - |
dc.description.abstract | Glioblastoma multiforme (GBM), a grade IV malignant astrocytic tumor according to WHO classification, is one of the most common and malignant brain tumor. Temozolomide (TMZ) is the current standard treatment for GBM. Nevertheless, resistance to chemotherapy in GBM is common and therefore a major obstacle to successful treatment. Adducin 3 (ADD3), a cytoskeletal protein, has been found to be associated with chemoresistance in osteosarcoma, but its potential role in glioblastoma is unclear. A TMZ-resistant model was established by chronically exposing the glioma cells (D54 cell line) to an increasing dose of TMZ. A resistant subclone (D54-R) was successfully generated. ADD3 expression level was found to be upregulated in the D54-R when compared to the parental D54 cells (D54-C). CD133 is a putative cancer stem cell marker. Its expression level was found also to be higher in D54-R when compared to D54-C cells. Among the D54-R cells, a subgroup of cells was found to express ADD3 intensely. The proportion of these spherical cells was higher in D54-R than D54-C. Moreover, these cells were spherical in morphology and expressed putative cancer stem cell markers: CD133, NANOG and OCT-3/-4. Therefore, ADD3 is associated with cancer stem cells in human glioma. The upregulation of ADD3 expression is associated with TMZ-resistance in GBM. | - |
dc.language | eng | - |
dc.publisher | The University of Hong Kong (Pokfulam, Hong Kong) | - |
dc.relation.ispartof | HKU Theses Online (HKUTO) | - |
dc.rights | The author retains all proprietary rights, (such as patent rights) and the right to use in future works. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.source.uri | http://hub.hku.hk/bib/B48335095 | - |
dc.subject.lcsh | Glioblastoma multiforme - Chemotherapy. | - |
dc.subject.lcsh | Drug resistance in cancer cells. | - |
dc.subject.lcsh | Cytoskeletal proteins. | - |
dc.title | Adducin 3 and temozolomide resistance in glioblastoma multiforme | - |
dc.type | PG_Thesis | - |
dc.identifier.hkul | b4833509 | - |
dc.description.thesisname | Master of Research in Medicine | - |
dc.description.thesislevel | Master | - |
dc.description.thesisdiscipline | Surgery | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.5353/th_b4833509 | - |
dc.date.hkucongregation | 2012 | - |
dc.identifier.mmsid | 991033835339703414 | - |